| Corneal Toxicity in Patients Treated by Belantamab Mafodotin (NCT05887206) | Centre Hospitalier Universitaire de Saint Etienne | 2022-05-02 |
| Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant (NCT05338047) | Hospital Universitario Dr. Jose E. Gonzalez | 2022-04-01 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (NCT04843579) | Weill Medical College of Cornell University | 2021-12-29 |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy (NCT04816526) | Cartesian Therapeutics | 2021-12-01 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma (NCT04782687) | US Oncology Research | 2021-09-10 |
| Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden (NCT04760184) | Uppsala University | 2021-04-01 |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM (NCT04009109) | Alliance Foundation Trials, LLC. | 2020-10-21 |
| CTFEA Myeloma Study (NCT04364724) | Tel-Aviv Sourasky Medical Center | 2020-06-01 |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (NCT04268199) | AHS Cancer Control Alberta | 2020-05-29 |
| The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood (NCT04242121) | Ivan S Moiseev | 2020-01-15 |
| Effect of Vitamin C in Autologous Stem Cell Transplantations (NCT03964688) | Maastricht University Medical Center | 2019-12-10 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma (NCT03910439) | National Cancer Institute (NCI) | 2019-10-17 |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors (NCT04236063) | University of Malaya | 2019-07-15 |
| Fluciclovine PET/CT in Multiple Myeloma Patients (NCT03966443) | Oslo University Hospital | 2019-03-01 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies (NCT03607643) | Leaf Vertical Inc. | 2019-01-15 |
| Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (NCT03992170) | Azienda Ospedaliera Universitaria Senese | 2018-12-31 |
| T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma (NCT03602612) | National Cancer Institute (NCI) | 2018-09-14 |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (NCT04065789) | Tel-Aviv Sourasky Medical Center | 2018-05-02 |
| Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma (NCT03191981) | University of Leeds | 2017-08-01 |
| CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma (NCT03150316) | Chong Kun Dang Pharmaceutical | 2017-05-10 |
| Collection of Additional Data Followed the Study IFM 2013-04 (NCT03089411) | Nantes University Hospital | 2017-03-20 |
| CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma (NCT03051841) | Chong Kun Dang Pharmaceutical | 2017-01-01 |
| Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma (NCT02447055) | Washington University School of Medicine | 2015-12-01 |
| Study of the Immune Response After Vaccination in Multiple Myeloma Patients (NCT02294487) | Wake Forest University Health Sciences | 2014-12-30 |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma (NCT02215967) | National Cancer Institute (NCI) | 2014-08-12 |
| Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma (NCT01239368) | National Cancer Institute (NCI) | 2010-11-10 |